ArticleBMC neurology2026
Role of serum complement C3 in blood-brain barrier injury and prognosis of anti-NMDAR encephalitis.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAnti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a rare autoimmune disease, with some patients experiencing poor clinical outcomes. Complement activation may contribute to disease progression, but its clinical significance remains unclear. This study investigated the correlation between serum complement C3 with blood–brain barrier (BBB) injury and prognosis in anti-NMDAR encephalitis.
methodsThis retrospective study enrolled 82 patients diagnosed with anti-NMDAR encephalitis at the Tianjin Huanhu Hospital. Spearman correlation analysis was used to assess the relationship between serum C3 level, disease severity, and BBB injury marker albumin quotient (Q-Alb). Binary logistic regression analysis and Cox proportional hazards models were used to investigate independent impact of serum C3 on disease prognosis and relapse. Sensitivity, interaction, and stratification analyses were performed to further verify the reliability of the results. Receiver operating characteristic curves were used to assess diagnostic value of serum C3 level for disease prognosis and relapse.
resultsThe median follow-up time of this study was 37.70 (24.23–55.72) months. Serum C3 level significantly positively correlated with the initial modified Rankin scale (mRS) scores (r = 0.327, P = 0.003) and Q-Alb (r = 0.307, P = 0.005). Mediation analysis showed that BBB injury mediated the effect of serum C3 on disease severity (P < 0.05). Multivariate logistic regression analysis showed that serum C3 was an independent risk factor for poor prognosis (odds ratio = 1.60, 95% confidence interval [CI] = 1.08–2.39, P = 0.020). Multivariate Cox analysis showed that serum C3 (hazard ratio [HR] = 1.32, 95% CI = 1.04–1.66, P = 0.023) and Q-Alb (HR = 1.14, 95% CI = 1.03–1.26, P = 0.009) were significant predictors of relapse.
conclusionBBB injury mediated the effect of serum C3 on disease severity in patients with anti-NMDAR encephalitis. Serum C3 was an independent risk factor for poor prognosis and disease relapse.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.